Generic Name and Formulations:
Liothyronine (as sodium) 10mcg/mL; soln for IV inj.
Indications for TRIOSTAT:
Give with glucocorticoids. Allow 4–12 hours between doses. Initially 25–50mcg. Cardiovascular disease: initially 10–20mcg. Usual range: 65–100mcg daily. Change to oral therapy as soon as possible: start tabs at low dose and increase gradually; discontinue IV gradually.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis. Artificial rewarming.
Not for treatment of obesity. Cardiovascular disease, angina, elderly: initiate therapy at 10–20micrograms. Severe and prolonged hypothyroidism. Fluid therapy. Adrenocortical insufficiency. Pregnancy (Cat.A). Nursing mothers.
Potentiates digitalis toxicity, tricyclic antidepressants, sympathomimetics (e.g., anorectics). May increase risk of coronary insufficiency with vasopressors. Monitor oral anticoagulants, hypoglycemics. Estrogens affect thyroid function tests. May be potentiated by tricyclic antidepressants. Hypertension, tachycardia with ketamine.
Arrhythmia, tachycardia, cardiopulmonary arrest, hypotension, MI, angina, CHF, hypertension, twitching.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|